Tozorakimab (MEDI-3506) is a human immunoglobulin G1 monoclonal antibody targeting IL-33. It inhibits IL-33 signaling through ST2 and RAGE/EGFR, reduces inflammation and epithelial dysfunction, and can be used to study chronic obstructive pulmonary disease.

5alpha-Hydroxycostic acid possesses anti-angiogenic ability by interfering the VEGF- and Ang2-related pathways, and it may be a good drug candidate.

β-Casomorphin (1-5) (bovine)